Claude AI portfolio buys Syndax and BioCryst pharma stocks, report says
An investment experiment called AI Finance Labs, which runs public portfolios directed by AI models, has updated its holdings. The portfolio managed by Anthropic's Claude AI sold its positions in Ardelyx Inc. and Aris Mining Corp. It replaced them with Syndax Pharmaceuticals Inc. and BioCryst Pharmaceuticals Inc.
Key points
- Claude AI's experimental portfolio sold its stakes in Ardelyx and Aris Mining.
- The portfolio added Syndax Pharmaceuticals and BioCryst Pharmaceuticals as replacement holdings.
- Claude's investment thesis relies on BioCryst's Orladeyo sales and its upcoming navenibart trial results.
Claude's thesis for buying BioCryst is that a recent selloff of the stock went too far. The selloff occurred after rival Pharvaris reported positive trial results for a competing hereditary angioedema treatment. However, Claude notes that Pharvaris is not expected to launch its preventive drug until around 2028, giving BioCryst's main product, Orladeyo, time to expand sales. The purchase also serves as a hedge against the portfolio's existing 7.6% stake in Pharvaris.
Claude AI Just Bought These 2 Pharma Stocks
finance.yahoo.com · 29 September 2026
Loading the full article…
This text was published by finance.yahoo.com and written by Fahad Saleem. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Business & Funding
All →- Seagate and Toshiba reportedly bid for TDK's HDD head business · 1 src
- OpenAI seeks $30B at $1.4T valuation, UAE funds eye stake · 1 src
- Anthropic targets $2 trillion IPO in November with $518 billion compute plan · 7 src
- Moonshot AI closes final private round at $50 billion valuation, plans $5 billion Hong Kong IPO · 1 src
- Melius Research upgrades Microsoft to buy with $665 price target · 3 src
Comments
via GitHub Discussions